Quantcast
Last updated on April 21, 2014 at 9:23 EDT

Latest AbbVie Stories

2013-10-04 08:23:53

NORTH CHICAGO, Ill., Oct. 4, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2013 financial results on Friday, Oct. 25, 2013, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time. About AbbVieAbbVie is a global,...

2013-10-03 08:29:05

-- The post-hoc analysis applies a new measurement tool created by AbbVie to assess the efficacy of HS therapy NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA(®) (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.(1) Efficacy results were reported using a novel Hidradenitis Suppurativa...

2013-09-24 08:31:14

Galapagos to host webcast presentation today at 15.00 CET/ 9 am ET/ 6 am PT NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide. AbbVie and Galapagos will work collaboratively...

2013-07-15 23:01:44

Are you taking any AbbVie drugs? David Healy & team want a report from you at RxISK.org. Toronto, Canada (PRWEB) July 15, 2013 RxISK.org, the first free independent website for researching and reporting prescription drug side effects, is helping a campaign to capture patient reported side effects of a range of drugs sold by the pharmaceutical company AbbVie - the recent spun-off entity of Abbott Laboratories. The campaign was announced by Dr. David Healy, a leading drug safety...

2013-07-08 08:27:14

New campaign with AbbVie features psoriasis-friendly style advice and educational resources designed to encourage people living with psoriasis to proactively confront their condition NORTH CHICAGO, Ill., July 8, 2013 /PRNewswire/ -- Stacy London, style expert and co-host of TLC's "What Not to Wear," today announced her partnership with AbbVie (NYSE: ABBV) on a new psoriasis campaign called Uncover Your Confidence. The campaign features educational resources and style advice for the...

2013-07-08 08:26:41

NORTH CHICAGO, Ill., July 8, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2013 financial results on Friday, July 26, 2013, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time. About AbbVieAbbVie is a global,...

2013-06-17 08:29:05

Analysis Evaluates Response Rates in Patients with 17p Deletion, Fludarabine-Refractory CLL NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients...

2013-06-11 12:28:55

Multinational, Multidisciplinary Expert Panel Reveals Survey Findings, Asks Patients to Take Pledge as Part of RA: Join the Fight, an AbbVie Global Initiative MADRID, June 11, 2013 /PRNewswire/ -- RA: Join the Fight today presented at a launch event in Madrid the findings from the largest global rheumatoid arthritis (RA) patient survey, which included 10,171 patients across 42 countries. Findings show that while a majority of RA patients (74 percent) say they know a great deal or a...

2013-06-05 08:29:26

NORTH CHICAGO, Ill., June 5, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 34(th) Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 12:40 p.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor...

2013-06-03 12:29:27

Data in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL)....